Previous 10 | Next 10 |
2023-05-04 11:18:55 ET Summary Icahn Enterprises crashed as the short seller report surfaced. The yield has gone to an incredible 25%. Can the legend Carl Icahn maintain this and take on Hindenburg? Let's find out. The market has a way of turning tables on the best o...
ALPHARETTA, Ga., May 02, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that its first quarter 2023 financial ...
ALPHARETTA, Ga., April 27, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that several key poster presentation...
2023-04-19 09:40:07 ET Summary It wasn't that many years ago that I was the Cornerstone fund's biggest detractor, writing negative articles as far back as 2012. That was at a time when the Cornerstone funds traded at market price premiums ranging from as high as 80%, even while th...
ALPHARETTA, Ga., April 19, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that multiple poster presentations w...
- Multiple U.S. Clinical Sites to Begin Enrolling ODYSSEY Participants This Quarter - - ODYSSEY Topline Results Expected in Q3 2024 - ALPHARETTA, Ga., April 18, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the deliv...
ALPHARETTA, Ga., April 12, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that George Lasezkay, Pharm.D., J.D....
ALPHARETTA, Ga., April 05, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), today announced the appointment of Arshad M. Khanani,...
2023-04-04 11:48:38 ET Summary What could go wrong with a fund near an all-time high 105% market price premium combined with a near all-time low NAV? Shareholders of the Gabelli Utility Trust may think they own a safe utility stock fund offering a very attractive 8.4% current mark...
- Initiation of Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected in Q2 2023 - - Medical Meeting Presentations Highlight Significant Potential of CLS-AX Based on Positive OASIS Phase 1/2a Safety Data, Durability, and Biologic Effect Over 6 Months - - Continued...
News, Short Squeeze, Breakout and More Instantly...
Cornerstone Strategic Value Fund Inc. Company Name:
CLM Stock Symbol:
NYSE Market:
ALPHARETTA, Ga., July 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), has opened registration for its virtual key opinion l...
ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today the appointment of Glenn C. Yiu, M.D....
- Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET - - Retina Specialists to Provide Insights and Real-World Experience with Suprachoroidal Drug Delivery - - Target Profile for CLS-AX in Wet AMD Landscape and Potential Opportunities for Clearside Pipeline Expansion - ...